Skip to Content
Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • William Blair Adds Senior Director in Europe

    William Blair announced today the expansion of the firm’s European team with the addition of Erik Westerink as senior director, Benelux, based in Amsterdam

    Read more
  • Year-End Wealth Planning and Philanthropy Strategies

    As 2026 draws to a close, now is the time to review your financial strategy and position yourself for success in the year ahead.

    Read more
  • Chroma Color Has Been Acquired by Wind Point Partners

    William Blair acted as the exclusive financial advisor to Chroma Color Corporation, a portfolio company of Arsenal Capital Partners, in connection with its sale to Wind Point Partners.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures